Joincare Pharmaceutical Group Industry Co.,Ltd. provided earnings guidance for the first nine months of 2018. For the period, the company predicts that net profit owned by shareholders will decrease by between RMB 1,379 million and RMB 1,414 million with a decrease of between 68.09% and 69.82% compared with the same period of the year before (based on the disclosed statistics according to relevant regulations). The net profit belonging to shareholders of the listed company after excluding extraordinary profit and loss will increase by between RMB 137 million and RMB 174 million with an increase of between 33.85% and 43.01% compared with the same period of the year before (based on the disclosed statistics according to relevant regulations).